Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained Japan Country Patent No. 7677628 for the HT-KIT platform. The patent was officially granted by the Japan Patent Office on May 7, 2025, and exclusive protection is granted until August 27, 2039.

The granted patent, titled "Targeting KIT with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells," protects Hoth's novel approach of using splice-switching oligonucleotides (SSOs) to selectively disrupt KIT gene expression in mast cells—cells implicated in conditions ranging from chronic hives to rare cancers.

"Securing intellectual property protection in Japan—a globally significant pharmaceutical market—underscores the global value of HT-KIT," said Robb Knie, CEO of Hoth Therapeutics. "We see strategic licensing potential across Asia as we move this asset forward."

Key Highlights

• Patent No. 7677628, granted by Japan Patent Office.
• Protection through 2039, ensuring long-term commercial exclusivity.
• Applicable to mast cell-driven inflammatory and oncologic conditions.
• Positioned for orphan indications and expedited regulatory pathways.

HT-KIT is one of several novel platforms under development at Hoth Therapeutics, which continues to seek strategic global partners, particularly in Asia, for co-development and commercialization opportunities.